KAPA

Kairos Pharma Ltd. (KAPA) | Rumor.io

Kairos Pharma

KAPA

Attention (50-day avg)0%

Attention rank (50-day avg)#1,498

Bullish sentiment (50-day avg)98%

Price to earnings ratio-5.67

Market capitalization5.7M

Earnings per share-1.96

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-5.4M

Social

What share of all stock conversation is about KAPA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Jul 31

Kairos Pharma, Ltd. has announced a strategic collaboration with Bayer to evaluate its core therapy, ENV-105, in combination with Xofigo for metastatic prostate cancer.
The company has reported positive interim Phase 1 safety data for ENV-105, with no serious treatment-related adverse events reported in the study.
Kairos Pharma is awaiting upcoming clinical milestones, including Phase 2 data evaluating ENV-105 in combination with apalutamide, and continued Phase 1/2 clinical readouts for ENV-105 in lung cancer.

Generated by AI

Sentiment

Of the messages about KAPA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	92.86% -7.14	84.57% -0.02
Bearish	0%	0% 0	7.14% +7.14	15.43% +0.02

Bullish· Jul 16

The asset's price has reached a new high, with some users predicting it will continue to rise and double in value.
The order book is thin, making it susceptible to a price surge with a few well-timed trades, and warrants are trading at a high price.
The asset has strong technical indicators, with all-time frames looking good, and is building momentum to break through key price levels.

Bearish· Sep 19

$KAPA's recent decline may be attributed to a thin float, which could lead to exaggerated price movements.
The company's cash position is a concern, with only 23.4 months of cash left based on its quarterly cash burn of -$0.76M.
Short sellers have been successful in manipulating the stock price, potentially due to hedge funds using fake price targets to short the stock.

Generated by AI

Topics

Of the messages about KAPA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	65.64%
Technical Analysis	—	0%	0%	13.41%
Analysts	—	0%	0%	13.97%
Macro	—	0%	0%	5.31%
Controversies	—	0%	0%	1.68%
Earnings	—	0%	0%	0%

Jul 15

$KAPA is expected to move up after consolidating in a cup/handle pattern, potentially breaking out to $2+.
The asset's MACD is crossing up, and a bull flag pattern has formed, indicating a potential increase in price.
A reversal is expected at $1.10, with the possibility of a bounce, but a failure to reverse at this point may lead to a further drop down.

Generated by AI

Community

Of the messages about KAPA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	50%	24.24%	11.56%	31.36%
Newcomers	50%	75.76%	88.44%	68.64%

Jul 31

The newcomers are focusing on the potential of Kairos Pharma's collaboration with Bayer, with one user comparing it to a similar success story with another stock.
The users are also excited about the company's ongoing clinical trials, including Phase 2 prostate cancer and Phase 1 lung cancer trials, which they believe could be catalysts for the stock's performance.
The newcomers are speculating about the stock's price, with one user saying it might run too and another user expressing love for the stock at its current levels.

Generated by AI

LOS ANGELES, September 23, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that Neil Bhowmick, President and Chief Scientific Officer, will both present and moderate a discussion in person at the 24th Annual Discovery on Target Drug Discovery Conference. The conference is being held on Sept. 28 to Oct. 1 at the Sheraton Boston Hotel with sessions available on demand on the conference’s website.

6d agoYahoo Finance

Kairos Pharma at H.C. Wainwright conference: resistance strategy in focus

15d agoInvesting.com

Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference

LOS ANGELES, September 09, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that John Yu, MD, CEO and Chairman, will present in person a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel.

21d agoYahoo Finance

Kairos Pharma to conduct 1-for-7 reverse stock split

1mo agoInvesting.com

Kairos Pharma Announces 1-for-7 Reverse Stock Split

LOS ANGELES, August 21, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-7 (the "Reverse Stock Split"). The Reverse Stock Split is expected to become effective on September 1, 2026 at 12:01 a.m. ET (the "Effective Time"), with shares expected to begin trading on the NYSE American on a spli

1mo agoYahoo Finance

Analysts Offer Insights on NA Companies: James Hardie Industries PLC (JHX) and Kairos Pharma, Ltd. (KAPA)

Detailed price information for James Hardie Industries Se ADR (JHX-N) from The Globe and Mail including charting and trades.

2mo agotheglobeandmail.com

Also Discussed

Investors talking about KAPA also mention

#	Name	Attention
1	Incannex Healthcare Inc.IXHL	0.01%0
2	Founder Group Ltd. Class A Ordinary SharesFGL	0%0
3	CleanCore Solutions Inc. Class B Common StockZONE	0%+0
4	NewGenIvf Group Limited Class A Ordinary SharesNIVF	0%0
5	VCI Global Ltd.VCIG	0%0
6	AtlasClear Holdings, Inc.ATCH	0.01%0
7	Globavend Holdings LimitedGVH	0%0
8	Rallybio Corp.RLYB	0%0
9	TNL Mediagene Ordinary SharesTNMG	0%new
10	Tharimmune Inc.THAR	0%new

Kairos Pharma Ltd.

Healthcare
Biotechnology

Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company focused on developing cancer therapeutics that address immune suppression and drug resistance. The company’s current portfolio centers on oncology candidates such as antibodies and small molecules designed to support immune function and target difficult-to-treat cancers, including prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma Ltd. also works on immunotherapy and cell therapy approaches, reflecting its emphasis on mechanisms that may help improve treatment response in cancer patients. Based in Los Angeles, California, the company operates in the biotechnology and pharmaceuticals sector, where it contributes to the development of experimental treatments intended for use in specialized oncology settings.

Website

Location

2355 Westwood Blvd.

Los Angeles, CA, 90064

United States

Social

What share of all stock conversation is about KAPA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Jul 31

Kairos Pharma, Ltd. has announced a strategic collaboration with Bayer to evaluate its core therapy, ENV-105, in combination with Xofigo for metastatic prostate cancer.
The company has reported positive interim Phase 1 safety data for ENV-105, with no serious treatment-related adverse events reported in the study.
Kairos Pharma is awaiting upcoming clinical milestones, including Phase 2 data evaluating ENV-105 in combination with apalutamide, and continued Phase 1/2 clinical readouts for ENV-105 in lung cancer.

Generated by AI

Sentiment

Of the messages about KAPA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	92.86% -7.14	84.57% -0.02
Bearish	0%	0% 0	7.14% +7.14	15.43% +0.02

Bullish· Jul 16

The asset's price has reached a new high, with some users predicting it will continue to rise and double in value.
The order book is thin, making it susceptible to a price surge with a few well-timed trades, and warrants are trading at a high price.
The asset has strong technical indicators, with all-time frames looking good, and is building momentum to break through key price levels.

Bearish· Sep 19

$KAPA's recent decline may be attributed to a thin float, which could lead to exaggerated price movements.
The company's cash position is a concern, with only 23.4 months of cash left based on its quarterly cash burn of -$0.76M.
Short sellers have been successful in manipulating the stock price, potentially due to hedge funds using fake price targets to short the stock.

Generated by AI

Topics

Of the messages about KAPA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	65.64%
Technical Analysis	—	0%	0%	13.41%
Analysts	—	0%	0%	13.97%
Macro	—	0%	0%	5.31%
Controversies	—	0%	0%	1.68%
Earnings	—	0%	0%	0%

Jul 15

$KAPA is expected to move up after consolidating in a cup/handle pattern, potentially breaking out to $2+.
The asset's MACD is crossing up, and a bull flag pattern has formed, indicating a potential increase in price.
A reversal is expected at $1.10, with the possibility of a bounce, but a failure to reverse at this point may lead to a further drop down.

Generated by AI

Community

Of the messages about KAPA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	50%	24.24%	11.56%	31.36%
Newcomers	50%	75.76%	88.44%	68.64%

Jul 31

The newcomers are focusing on the potential of Kairos Pharma's collaboration with Bayer, with one user comparing it to a similar success story with another stock.
The users are also excited about the company's ongoing clinical trials, including Phase 2 prostate cancer and Phase 1 lung cancer trials, which they believe could be catalysts for the stock's performance.
The newcomers are speculating about the stock's price, with one user saying it might run too and another user expressing love for the stock at its current levels.

Generated by AI

Kairos Pharma

Social

Jul 31

Sentiment

Bullish· Jul 16

Bearish· Sep 19

Topics

Jul 15

Community

Jul 31

News

Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA

Kairos Pharma at H.C. Wainwright conference: resistance strategy in focus

Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Kairos Pharma to conduct 1-for-7 reverse stock split

Kairos Pharma Announces 1-for-7 Reverse Stock Split

Analysts Offer Insights on NA Companies: James Hardie Industries PLC (JHX) and Kairos Pharma, Ltd. (KAPA)

Also Discussed

Kairos Pharma Ltd.

Company Information

Location

News

Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA

Kairos Pharma at H.C. Wainwright conference: resistance strategy in focus

Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Kairos Pharma to conduct 1-for-7 reverse stock split

Kairos Pharma Announces 1-for-7 Reverse Stock Split

Analysts Offer Insights on NA Companies: James Hardie Industries PLC (JHX) and Kairos Pharma, Ltd. (KAPA)

Also Discussed

Social

Jul 31

Sentiment

Bullish· Jul 16

Bearish· Sep 19

Topics

Jul 15

Community

Jul 31